The Medicare Access & CHIP Reauthorization Act of 2015 (MACRA) is a game-changing development for health care delivery that began implementation in January 2017. Significant changes are now underway as providers and payers determine how to best implement MACRA and navigate the accelerating shift from volume to value that MACRA is designed to drive. The implications for MedTech companies are far-reaching in terms of the changing customer base and buying behaviors, demands for evidence, and opportunities to support customers across the continuum of care settings. In this discussion, we will cover:
• Briefing on MACRA: how it changes provider and payer reimbursement and drives incentives to modify behavior and business models
• Emerging archetypes and market characteristics to consider
• Implications for MedTech companies – the new imperatives for success and what to watch for in coming months
Join Deloitte Consulting LLP and Medical Alley for a discussion that brings our industry perspective of provider and payer actions under MACRA and how that will impact the Medical Technology market.